139 related articles for article (PubMed ID: 35977881)
1. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
[TBL] [Abstract][Full Text] [Related]
2. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M; Koçak MZ; Dinç G; Genç TB; Çağlayan M; Uğraklı S; Hendem E; Er MM; Çağlayan D; Eryılmaz MK; Araz M; Geredeli Ç; Tatlı AM; Eren OÖ; Artaç M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9183-9189. PubMed ID: 37184681
[TBL] [Abstract][Full Text] [Related]
3. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J; Dalban C; Laguerre B; Ladoire S; Barthélémy P; Oudard S; Joly F; Gravis G; Chevreau C; Geoffrois L; Deluche É; Rolland F; Topart D; Culine S; Négrier S; Mahammedi H; Tantot F; Jamet A; Escudier B; Flippot R; Albigès L
Eur Urol; 2021 Sep; 80(3):325-329. PubMed ID: 34103181
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Mourey L; Rainho LT; Dalban C; Carril-Ajuria L; Negrier S; Chevreau C; Gravis G; Thibault C; Laguerre B; Barthelemy P; Borchiellini D; Gross-Goupil M; Geoffrois L; Rolland F; Thiery-Vuillemin A; Tantot F; Chaput N; Naigeon M; Teixeira M; Escudier B; Flippot R; Albiges L
Eur J Cancer; 2024 Apr; 201():113589. PubMed ID: 38382153
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
6. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
7. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M; Dalban C; Chevreau C; Gravis G; Negrier S; Laguerre B; Gross-Goupil M; Ladoire S; Borchiellini D; Geoffrois L; Joly F; Priou F; Barthelemy P; Laramas M; Narciso B; Thiery-Vuillemin A; Berdah JF; Ferrari V; Dominique Thomas Q; Mione C; Curcio H; Oudard S; Tantot F; Escudier B; Chabaud S; Albiges L; Thibault C
Eur J Cancer; 2023 Mar; 182():66-76. PubMed ID: 36746010
[TBL] [Abstract][Full Text] [Related]
9. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
10. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E; Dalban C; Oudard S; Chevreau C; Laguerre B; Barthélémy P; Borchiellini D; Geoffrois L; Negrier S; Joly F; Thiery-Vuillemin A; Gross-Goupil M; Rolland F; Priou F; Mahammedi H; Tantot F; Escudier B; Chabaud S; Albiges L; Gravis G
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37813745
[TBL] [Abstract][Full Text] [Related]
11. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
[TBL] [Abstract][Full Text] [Related]
12. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
13. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L; Desnoyer A; Meylan M; Dalban C; Naigeon M; Cassard L; Vano Y; Rioux-Leclercq N; Chouaib S; Beuselinck B; Chabaud S; Barros-Monteiro J; Bougoüin A; Lacroix G; Colina-Moreno I; Tantot F; Boselli L; De Oliveira C; Fridman WH; Escudier B; Sautes-Fridman C; Albiges L; Chaput-Gras N
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640928
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
[TBL] [Abstract][Full Text] [Related]
15. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
Billon E; Chanez B; Rochigneux P; Albiges L; Vicier C; Pignot G; Walz J; Chretien AS; Gravis G; Olive D
Front Immunol; 2021; 12():670827. PubMed ID: 33959132
[TBL] [Abstract][Full Text] [Related]
16. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
[TBL] [Abstract][Full Text] [Related]
17. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Guilhem-Ducléon G; Dalban C; Negrier S; Gravis G; Laguerre B; Chevreau C; Oudard S; Barthelemy P; Ladoire S; Boughalem E; Borchiellini D; Linassier C; Nenan S; Flippot R; Albiges L; Goupil MG
Clin Genitourin Cancer; 2023 Dec; 21(6):643-652. PubMed ID: 37635052
[TBL] [Abstract][Full Text] [Related]
18. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
Mollica V; Santoni M; Matrana MR; Basso U; De Giorgi U; Rizzo A; Maruzzo M; Marchetti A; Rosellini M; Bleve S; Maslov D; Tawagi K; Philon E; Blake Z; Massari F
Target Oncol; 2022 Jan; 17(1):61-68. PubMed ID: 34894318
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
